financetom
Business
financetom
/
Business
/
Exclusive-Blackstone evaluates taking a stake in US TikTok spinoff, sources say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Exclusive-Blackstone evaluates taking a stake in US TikTok spinoff, sources say
Mar 28, 2025 2:10 PM

(Reuters) -Private equity firm Blackstone is evaluating taking a small minority investment in TikTok's U.S. operations, according to two people familiar with the matter.

Blackstone is discussing joining Chinese parent company ByteDance's existing non-Chinese shareholders, led by Susquehanna International Group and General Atlantic, in a bid for TikTok's U.S. business. The group has emerged as front-runners.

Their proposal entails spinning off TikTok's U.S. operations into a separate entity and diluting Chinese ownership in the new business to below the 20% threshold required by U.S. law.

TikTok, General Atlantic, and Blackstone declined to comment. Susquehanna did not respond to a request seeking comment.

The fate of the app used by nearly half of all Americans has been up in the air since a law, passed last year with overwhelming bipartisan support, required ByteDance to divest TikTok by January 19 or face a ban on national security grounds.

TikTok briefly went dark in the U.S. in January after the Supreme Court upheld the ban, but flickered back to life days later once U.S. President Donald Trump took office and postponed enforcement of the law to April 5.

Trump has said he may extend that deadline further and dangled a possible reduction in tariffs on China to try to get a deal done. U.S. Vice President JD Vance said he expects the general terms of an agreement that resolves ownership of the app to be reached by the April deadline.

ByteDance and its investors have not disclosed how much fresh investment would be needed to buy out Chinese shareholders and meet the requirements of the U.S. law. 

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lucid Group, Graphite One Sign Agreement for Anode Materials Supply
Lucid Group, Graphite One Sign Agreement for Anode Materials Supply
Jul 29, 2024
11:46 AM EDT, 07/29/2024 (MT Newswires) -- Lucid Group ( LCID ) and Graphite One signed a non-binding supply agreement for anode active materials, Graphite One said Monday. The agreement initiates a 100% US-based supply chain connecting Alaska, Ohio and Arizona, Graphite One said. Financial details were not disclosed. ...
Update: Collective Mining Gains 3.6% as It Reports Latest Assays from the Trap Target in Colombia
Update: Collective Mining Gains 3.6% as It Reports Latest Assays from the Trap Target in Colombia
Jul 29, 2024
11:43 AM EDT, 07/29/2024 (MT Newswires) -- Collective Mining ( CNL ) on Monday reported assays for four holes drilled at the Trap target within the company's Guayabales project in Colombia. Highlights include 40.85 meters at 3.76 grams per tonne (g/t) gold equivalent within 174.45 meters at 1.19 gold equivalent. The company said the Trap target can rapidly evolve through...
Sarepta Therapeutics Poised for 'Significant Launch Inflection' Amid Positive Elevidys Feedback, RBC Says
Sarepta Therapeutics Poised for 'Significant Launch Inflection' Amid Positive Elevidys Feedback, RBC Says
Jul 29, 2024
11:41 AM EDT, 07/29/2024 (MT Newswires) -- Sarepta Therapeutics' ( SRPT ) Elevidys, a gene therapy for the treatment of Duchenne muscular dystrophy, or DMD, has drawn high interest from physicians and patients, RBC Capital Markets said in a report Monday. The investment firm also said concerns around treatment throughput, center capacity, and manufacturing supply seem to be overdone following...
Compugen Gets US FDA Approval for Solid Tumor Treatment Study
Compugen Gets US FDA Approval for Solid Tumor Treatment Study
Jul 29, 2024
11:19 AM EDT, 07/29/2024 (MT Newswires) -- Compugen ( CGEN ) said Monday that the US Food and Drug Administration approved the company's investigational new drug application to start a phase 1 trial for COM503 as a potential treatment for patients with solid tumors. The trial will evaluate COM503 as a monotherapy and in combination with Gilead Sciences' ( GILD...
Copyright 2023-2026 - www.financetom.com All Rights Reserved